Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HMGCR | P04035 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 3/20 | 0.43 |
| ▸ | CPT2 | P23786 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30017023 | 0.96 | ALDH1A1 (0.53) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL29363039 | 0.96 | ALDH1A1 (0.53) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Ammonia Solution, Strong SCHEMBL29372545 | 0.93 | ALDH1A1 (0.50) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Water SCHEMBL29581041 | 0.93 | ALDH1A1 (0.50) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL7039700 | 0.83 | ALDH1A1 (0.48) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL2421001 | 0.81 | HMGCR (0.52) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL380759 | 0.81 | HMGCR (0.52) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL11507779 | 0.81 | MVD (0.47) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL15728325 | 0.81 | ALDH1A1 (0.40) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL7654599 | 0.78 | ALDH1A1 (0.43) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224437-A1 | BIOMARKERS FOR LUNG CANCER | ABERYSTWYTH UNIVERSITY (GB) | 2025-10-30 | — | — | WO | claimed |
| EP-3707193-A1 | DENDRIMER DELIVERY SYSTEM AND METHODS OF USE THEREOF | The Johns Hopkins University (US) | 2020-09-16 | — | — | EP | claimed |
| CN-111615528-A | Dendrimer delivery systems and methods of use thereof | 约翰霍普金斯大学 | 2020-09-01 | — | — | CN | claimed |
| US-20190142964-A1 | DENDRIMER DELIVERY SYSTEM AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. | 2019-05-16 | — | — | US | claimed |
| EP-1070748-A1 | Powder coating compositions, their preparation and use | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-01-24 | — | — | EP | claimed |
| US-6114489-A | POWDER COATING COMPOSITIONS CONTAINING NOVEL ALIPHATIC HYPERBRANCHED POLYESTER POLYMERS, WHICH FUNCTION EITHER AS POLYMERIC CROSSLINKERS OR AS FLOW AND LEVELING AGENTS | HERBERTS GMBH (DE) | 2000-09-05 | — | — | US | claimed |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | UNIV JOHNS HOPKINS (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250352653-A1 | NEURON TARGETED 2-DEOXYGLUCOSE DENDRIMER FOR IMAGING AND TREATMENT OF NEUROLOGICAL DISEASES | UNIV WASHINGTON STATE (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025224437-A1 | BIOMARKERS FOR LUNG CANCER | ABERYSTWYTH UNIVERSITY (GB) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025224437-A1 | BIOMARKERS FOR LUNG CANCER | ABERYSTWYTH UNIVERSITY (GB) | 2025-10-30 | — | — | WO | disclosed |
| US-20250269044-A1 | PSMA-TARGETED DENDRIMER NANOPLATFORM FOR CANCER DETECTION AND THERAPY | WASHINGTON STATE UNIVERSITY | 2025-08-28 | — | — | US | disclosed |
| EP-4577246-A1 | DENDRIMER CONJUGATES OF ANTIDEPRESSANT AND ANTIPSYCHOTIC AGENTS AND THEIR METHODS OF USE | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4577245-A1 | DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF PSYCHEDELIC THERAPEUTICS | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20090239949-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239949-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2009-09-24 | — | — | US | disclosed |
| US-20080207757-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207757-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
| WO-2008098151-A2 | POLAR HYDROPHILIC PRODRUGS OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| EP-1070748-A1 | Powder coating compositions, their preparation and use | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-01-24 | — | — | EP | disclosed |
| US-6114489-A | POWDER COATING COMPOSITIONS CONTAINING NOVEL ALIPHATIC HYPERBRANCHED POLYESTER POLYMERS, WHICH FUNCTION EITHER AS POLYMERIC CROSSLINKERS OR AS FLOW AND LEVELING AGENTS | HERBERTS GMBH (DE) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239949-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A2, SLC6A3, SLC18A2 | ALDH1A1 1191/4885HMGCR 2980/4885CHRM1 60/4885 |
| US-20190142964-A1 | DENDRIMER DELIVERY SYSTEM AND METHODS OF USE THEREOF | TLR3, CD40LG, OXGR1 | ALDH1A1 2712/4885HMGCR 2130/4885CHRM1 685/4885 |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | CNR1, CNR2, GPR18 | ALDH1A1 3449/4885HMGCR 3182/4885CHRM1 547/4885 |
| US-20080207757-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A2, SLC6A3, SLC18A2 | ALDH1A1 1191/4885HMGCR 2980/4885CHRM1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.